Lead, calcium uptake, and related genetic variants in association with renal cell carcinoma risk in a cohort of male finnish smokers

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 1, 2012, Pages 191-201

  Southard, Emily B ^a   Roff, Alanna ^a   Fortugno, Tracey ^a   Richie, John P ^a   Kaag, Matthew ^a   Chinchilli, Vernon M ^a   Virtamo, Jarmo ^b   Albanes, Demetrius ^c   Weinstein, Stephanie ^c   Wilson, Robin Taylor ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALBINDIN; CALCIUM; LEAD; VANILLOID RECEPTOR 5; VANILLOID RECEPTOR 6;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM TRANSPORT; CANCER PROGNOSIS; CANCER RISK; DISEASE ASSOCIATION; FINLAND; FOLLOW UP; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; LEAD BLOOD LEVEL; LEAD POISONING; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

EID: 84855518335     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0670     Document Type: Article

References (69)

1. Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH. Global increases in kidney cancer incidence, 1973-1992. 2002;11:171-8.
2. Ward EM, Thun MJ, Hannan LM, Jemal A. Interpreting cancer trends. Ann N Y Acad Sci 2006;1076:29-53. (Pubitemid 44955247)
3. Wilson RT, Richardson LC, Kelly JJ, Kaur J, Jim MA, Lanier AP. Cancers of the urinary tract among American Indians and Alaska Natives in the United States, 1999-2004. Cancer 2008;113:1213-24.
4. Moore LE, Wilson RT, Campleman SL. Lifestyle factors, exposures, genetic susceptibility and renal cell cancer risk: a review. Cancer Res 2005;23:240-55. (Pubitemid 40770742)
5. Brannon AR, Rathmell WK. Renal cell carcinoma: where will the state-of-the-art lead us? Curr Oncol Rep 2010;12:193-201.
6. International Agency for Research on Cancer. In: IAfROC, editor. Inorganic and organic lead compounds. Lyon, France: IARC; 2006.
7. Mielke HW, Laidlaw MA, Gonzales CR. Estimation of leaded (Pb) gasoline's continuing material and health impacts on 90 US urbanized areas. Environ Int 2011;37:248-57.
8. Edwards M, Triantafyllidou S, Best D. Elevated blood lead in young children due to lead-contaminated drinking water: Washington, DC, 2001-2004. Environ Sci Technol 2009;43:1618-23.
9. Silbergeld EK, Waalkes M, Rice JM. Lead as a carcinogen: experimental evidence and mechanisms of action. Am J Ind Med 2000;38:316-23. (Pubitemid 30648762)
10. Silbergeld EK. Facilitative mechanisms of lead as a carcinogen. Mutat Res 2003;533:121-33. (Pubitemid 37487864)
11. Fu H, Boffetta P. Cancer and occupational exposure to inorganic lead compounds: a meta-analysis of published data. Occup Environ Med 1995;52:73-81.
12. Fullmer CS. Lead-calcium interactions: involvement of 1,25-dihydroxyvitamin D. Environ Res 1997;72:45-55. (Pubitemid 27053557)
13. Dowd TL, Rosen JF, Gundberg CM, Gupta RK. The displacement of calcium from osteocalcin at submicromolar concentrations of free lead. Biochim Biophys Acta 1994;1226:131-7. (Pubitemid 24182456)
14. Hart MH, Smith JL. Effect of vitamin D and low dietary calcium on lead uptake and retention in rats. J Nutr 1981;111:694-8. (Pubitemid 11076670)
15. Campbell JR, Auinger P. The association between blood lead levels and osteoporosis among adults-results from the third national health and nutrition examination survey (NHANES III). Environ Health Perspect 2007;115:1018-22. (Pubitemid 47317065)
16. Khalil N, Cauley JA, Wilson JW, Talbott EO, Morrow L, Hochberg MC, et al. Relationship of blood lead levels to incident nonspine fractures and falls in older women: the study of osteoporotic fractures. J Bone Miner Res 2008;23:1417-25.
17. Olivi L, Cascio S, Wang S, Bressler J. Mobilization of intracellular calcium in kidney epithelial cells is inhibited by lead. Toxicology 2002;176:1-9. (Pubitemid 34626727)
18. Pokorski PL, McCabe MJ Jr, Pounds JG. Lead inhibits meso-2,3- dimercaptosuccinic acid induced calciumtransients in cultured rhesus monkey kidney cells. Toxicology 1999;134:19-26. (Pubitemid 29243774)
19. Mellemgaard A, McLaughlin J, Overvad K, Olsen J. Dietary risk factors for renal cell carcinoma in Denmark. Eur J Cancer 1996;32A:673-82.
20. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al. Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) 2009;1-420.
21. Boros S, Bindels RJ, Hoenderop JG. Active Ca(2+) reabsorption in the connecting tubule. Pflugers Arch 2009;458:99-109.
22. Lupp A, Klenk C, Rocken C, Evert M, Mawrin C, Schulz S. Immunohistochemical identification of the PTHR1 parathyroid hormone receptor in normal and neoplastic human tissues. Eur J Endocrinol 2010;162:979-86.
23. Weaver VM, Lee BK, Todd AC, Ahn KD, Shi W, Jaar BG, et al. Effect modification by delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and renal function in lead workers. Environ Res 2006;102:61-9. (Pubitemid 44080200)
24. Schwartz BS, Lee BK, Lee GS, Stewart WF, Simon D, Kelsey K, et al. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and [delta]-aminolevulinic acid dehydratase genes. Environ Health Perspect 2000;108:949-54.
25. Kelada SN, Shelton E, Kaufmann RB, Khoury MJ. Delta-aminolevulinic acid dehydratase genotype and lead toxicity: a HuGE review. Am J Epidemiol 2001;154:1-13. (Pubitemid 32565680)
26. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994;4:1-10.
27. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002;41:381-8.
28. Pietinen P, Hartman AM, Haapa E, Rasanen L, Haapakoski J, Palmgren J, et al. Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol 1988;128:655-66.
29. Gallicchio L, Moore LE, Stevens VL, Ahn J, Albanes D, Hartmuller V, et al. Circulating 25-hydroxyvitamin D and risk of kidney cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172(1):47-57.
30. BIOBASE. Available from: http://www.biobase-international.com/product/ transcription-factor-binding-sites. Date last accessed: November 30, 2011.
31. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006;34:D108-10.
32. Chow WH, Devesa SS, Moore LE. Epidemiology of renal cell carcinoma. In:Vogelzang NJ, Scardino PJ, Shipley WU, Debruyne FMJ, Linehan WM, editors. Comprehensive textbook of genitourinary oncology. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 110.
33. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol 2007;166:932-40. (Pubitemid 47511687)
34. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-80. (Pubitemid 27198985)
35. Gill RK, Christakos S. Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl Acad Sci U S A 1993;90:2984-8. (Pubitemid 23113542)
36. Valouev A, Johnson DS, Sundquist A, Medina C, Anton E, Batzoglou S, et al. Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 2008;5:829-34.
37. Oliver T. Lead poisoning, from the industrial, medical, and social points of view: lectures delivered at the Royal Institute of Public Health. JAMA 1915;LXIV(21):1785.
38. Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med 2000;38:244-54. (Pubitemid 30648759)
39. Wang Y, Jacobs EJ, McCullough ML, Rodriguez C, Thun MJ, Calle EE, et al. Comparing methods for accounting for seasonal variability in a biomarker when only a single sample is available: insights from simulations based on serum 25-hydroxyvitamin d. Am J Epidemiol 2009;170:88-94.
40. Conterato GM, Augusti PR, Somacal S, Einsfeld L, Sobieski R, Torres JR, et al. Effect of lead acetate on cytosolic thioredoxin reductase activity and oxidative stress parameters in rat kidneys. Basic Clin Pharmacol Toxicol 2007;101:96-100. (Pubitemid 47094302)
41. Cerulli N, Campanella L, Grossi R, Politi L, Scandurra R, Soda G, et al. Determination of Cd, Cu, Pb and Zn in neoplastic kidneys and in renal tissue of fetuses, newborns and corpses. J Trace Elem Med Biol 2006;20:171-9. (Pubitemid 44311015)
42. Schober SE, Mirel LB, Graubard BI, Brody DJ, Flegal KM. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. Environ Health Perspect 2006;114:1538-41. (Pubitemid 44509651)
43. Jemal A, Graubard BI, Devesa SS, Flegal KM. The association of blood lead level and cancer mortality among whites in the United States. Environ Health Perspect 2002;110:325-9. (Pubitemid 34308594)
44. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 2002;162:2443-9. (Pubitemid 35340460)
45. Bogden JD, Gertner SB, Kemp FW, McLeod R, Bruening KS, Chung HR. Dietary lead and calcium: effects on blood pressure and renal neoplasia in Wistar rats. J Nutr 1991;121:718-28.
46. Weaver VM, Schwartz BS, Ahn KD, Stewart WF, Kelsey KT, Todd AC, et al. Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers. Environ Health Perspect 2003;111:1613-9. (Pubitemid 37265972)
47. Silbergeld EK. Preventing lead poisoning in children. Annu Rev Public Health 1997;18:187-210. (Pubitemid 27194069)
48. Nordman CH, Hernberg S. Blood lead levels and erythrocyte delta-amino-levulinic acid dehydratase activity of selected population groups in Helsinki. Scand J Work Environ Health 1975;1:219-32.
49. Barbosa F Jr, Tanus-Santos JE, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. Environ Health Perspect 2005;113:1669-74. (Pubitemid 41794259)
50. Ahamed M, Siddiqui MK. Environmental lead toxicity and nutritional factors. Clin Nutr 2007;26:400-8. (Pubitemid 47091485)
51. Peterlik M, Cross HS. Vitamin D and calcium deficits predispose for multiple chronic diseases. Eur J Clin Invest 2005;35:290-304. (Pubitemid 40675603)
52. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002;94:437-46. (Pubitemid 34285093)
53. Prineas R, Folsom A, Zhang Z, Sellers T, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997;8:31-6. (Pubitemid 27014218)
54. Hu J, Mao Y, White K. Diet and vitamin or mineral supplements and risk of renal cell carcinoma in Canada. Cancer Causes Control 2003;14:705-14. (Pubitemid 37463883)
55. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008;100:1581-91.
56. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-96. (Pubitemid 43247139)
57. Na T, Zhang W, Jiang Y, Liang Y, Ma HP, Warnock DG, et al. The A563T variation of the renal epithelial calcium channel TRPV5 among African Americans enhances calcium influx. Am J Physiol Renal Physiol 2009;296:F1042-51.
58. Hughes DA, Tang K, Strotmann R, Schoneberg T, Prenen J, Nilius B, et al. Parallel selection on TRPV6 in human populations. PLoS One 2008;3:e1686.
59. Suzuki Y, Pasch A, Bonny O, Mohaupt MG, Hediger MA, Frey FJ. Gain-of-function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation. Hum Mol Genet 2008;17:1613-8. (Pubitemid 351737165)
60. Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh JC, Zitzer H, et al. The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 2000;14:401-20. (Pubitemid 32260532)
61. Hoenderop JG, Nilius B, Bindels RJ. Molecular mechanism of active Ca2 +reabsorption in the distal nephron. Annu Rev Physiol 2002;64:529-49. (Pubitemid 34259239)
62. Sooy K, Kohut J, Christakos S. The role of calbindin and 1,25dihydroxyvitamin D3 in the kidney. Curr Opin Nephrol Hypertens 2000;9: 341-7.
63. Petrazzuolo O, Trepiccione F, Zacchia M, Capasso G. Hypertension and renal calcium transport. J Nephrol 2010;23 Suppl 16:S112-7.
64. Christakos S, Liu Y. Biological actions and mechanism of action of calbindin in the process of apoptosis. J Steroid Biochem Mol Biol 2004;89-90:401-4. (Pubitemid 38844319)
65. Hobbs CA, Deterding LJ, Perera L, Bobay BG, Thompson RJ, Darden TA, et al. Structural characterization of the conformational change in calbindin-D28k upon calcium binding using differential surface modification analyzed by mass spectrometry. Biochemistry 2009;48:8603-14.
66. Kojetin DJ, Venters RA, Kordys DR, Thompson RJ, Kumar R, Cavanagh J. Structure, binding interface and hydrophobic transitions of Ca2+-loaded calbindin-D(28K). Nat Struct Mol Biol 2006;13:641-7. (Pubitemid 44036475)
67. Magera JS Jr, Leibovich BC, Lohse CM, Sengupta S, Cheville JC, Kwon ED, et al. Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma. Urology 2008;71:278-82. (Pubitemid 351282342)
68. Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011;22:295-300.
69. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110:543-50. (Pubitemid 47106142)